FOXP1 regulation via the PI3K/Akt/p70S6K signaling pathway in breast cancer cells

Oncology Letters

Volumn 9, Issue 3, 2015, Pages 1482-1488

  Halacli, Sevil Oskay ^a   Dogan, Ayse Lale ^b  

^a Institute of Child Health   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Akt; Breast cancer; Forkhead box P1; P70S6 kinase; Phosphatidylinositol 3 kinase

Indexed keywords

EPIDERMAL GROWTH FACTOR; GREEN FLUORESCENT PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PEPTIDES AND PROTEINS; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PROTEIN KINASE B; RESTRICTION ENDONUCLEASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG; WORTMANNIN;

ARTICLE; BREAST CANCER; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

EID: 84921745023     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.2885     Document Type: Article

References (32)

1. Beelen K, Hoefnagel LD, Opdam M, et al: PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy. Int J Cancer 135: 1257-1263, 2014.
2. Zhang Y, Tseng CC, Tsai YL, et al: Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI(3,4,5)P3 production. PLoS One 8: e80071, 2013.
3. Chin YR and Toker A: Akt isoform-specific signaling in breast cancer: uncovering an anti-migratory role for palladin. Cell Adh Migr 5: 211-214, 2011.
4. Shin S, Wolgamott L, Yu Y, et al: Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation. Proc Natl Acad Sci USA 108: E1204-E1213, 2011.
5. Matassa DS, Agliarulo I, Amoroso MR, et al: TRAP1-dependent regulation of p70S6K is involved in the attenuation of protein synthesis and cell migration: Relevance in human colorectal tumors. Mol Oncol 8: 1482-1494, 2014.
6. Segatto I, Berton S, Sonego M, et al: p70S6 kinase mediates breast cancer cell survival in response to surgical wound fluid stimulation. Mol Oncol 8: 766-780, 2014.
7. Plas DR and Thompson CB: Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem 278: 12361-12366, 2003.
8. Brunet A, Bonni A, Zigmond MJ, et al: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868, 1999.
9. Biggs WH III, Meisenhelder J, Hunter T, et al: Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA 96: 7421-7426, 1999.
10. van Boxtel R, Gomez-Puerto C, Mokry M, et al: FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis. Cell Death Differ 20: 1219-1229, 2013.
11. Banham AH, Beasley N, Campo E, et al: The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res 61: 8820-8829, 2001.
12. Brown PJ, Ashe SL, Leich E, et al: Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. Blood 111: 2816-2824, 2008.
13. Bates GJ, Fox SB, Han C, et al: Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas. Breast Cancer Res Treat 111: 453-459, 2008.
14. Shigekawa T, Ijichi N, Ikeda K, et al: FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer. Horm Cancer 2: 286-297, 2011.
15. Banham AH, Boddy J, Launchbury R, et al: Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia. Prostate 67: 1091-1098, 2007.
16. Rayoo M, Yan M, Takano EA, et al: Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers. J Clin Pathol 62: 896-902, 2009.
17. McMahon LP, Yue W, Santen RJ and Lawrence JC Jr: Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex. Mol Endocrinol 19: 175-183, 2005.
18. Tiwary R, Yu W, Sanders BG and Kline K: α-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways. Br J Cancer 104: 101-109, 2011.
19. Carracedo A, Ma L, Teruya-Feldstein J, et al: Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074, 2008.
20. Sangai T, Akcakanat A, Chen H, et al: Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res 18: 5816-5828, 2012.
21. Noh WC, Mondesire WH, Peng J, et al: Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10: 1013-1023, 2004.
22. Yellen P, Saqcena M, Salloum D, et al: High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 10: 3948-3956, 2011.
23. Chen Y, Zheng Y and Foster DA: Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene 22: 3937-3942, 2003.
24. Meric-Bernstam F, Akcakanat A, Chen H, et al: PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 18: 1777-1789, 2012.
25. O'Reilly KE, Rojo F, She QB, et al: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508, 2006.
26. Breuleux M, Klopfenstein M, Stephan C, et al: Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 8: 742-753, 2009.
27. Holz MK and Blenis J: Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem 280: 26089-26093, 2005.
28. Holz MK, Ballif BA, Gygi SP and Blenis J: mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123: 569-580, 2005.
29. Gomez GG, Volinia S, Croce CM, et al: Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. Cancer Res 74: 1429-1439, 2014.
30. Qin J, Xu Y, Li X, et al: Effects of lentiviral-mediated Foxp1 and Foxq1 RNAi on the hepatocarcinoma cell. Exp Mol Pathol 96: 1-8, 2014.
31. Feng J, Zhang X, Zhu H, et al: High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer. Am J Clin Pathol 138: 230-235, 2012.
32. Krohn A, Seidel A, Burkhardt L, et al: Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. J Pathol 231: 130-141, 2013.